As analysts predicted, the data coming out of embargo during the annual meeting of the American Association for the Study of Liver Disease (AASLD) don't appear to be triggering any major swings in biotech stock prices. (BioWorld Today)

At the third annual BIOCOM Investor Conference, held last week in San Diego, former Cowen & Co. vice chairman Stelios Papadopoulos gave the industry reason to believe that this, too, shall pass. (BioWorld Financial Watch)

Biogen Idec Inc. said it will pay a $31.5 million up-front fee to join Genentech Inc. and F. Hoffmann-La Roche Ltd. in the development of a humanized anti-CD20 monoclonal antibody, GA101. (BioWorld Today)